Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
MWN-AI** Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) recently announced its participation in the International Congress of Parkinson’s Disease and Movement Disorders, scheduled from October 5-9, 2025, in Honolulu, Hawaii. The company is set to present significant updates from its diverse pipeline, including preclinical efficacy and safety data for its investigational drug, ACP-711, aimed at treating essential tremor. Additionally, Acadia will discuss the design of its Phase 2 ACP-204 study focused on adults suffering from Lewy body dementia psychosis.
The highlight of Acadia's presentations will be a late-breaker oral platform presentation titled "Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of SAN711/ACP-711, a Novel GABA A Subunit ? 3 Selective Modulator," scheduled for October 8. This will provide insights into the drug's mechanism and its potential therapeutic implications.
Moreover, Acadia will feature two poster presentations. One will detail the study design of the Phase 2, double-blind trial of ACP-204 as a treatment for Lewy body dementia psychosis, while the second will analyze clinical trial data concerning the duration of illness and response to NUPLAZID® (pimavanserin) in Parkinson’s disease psychosis. This post-hoc analysis aims to deepen the understanding of how duration impacts treatment outcomes.
Acadia continues to position itself as a leader in treating underserved neurological disorders with its FDA-approved NUPLAZID, used for managing hallucinations and delusions related to Parkinson’s disease psychosis. The company emphasizes its commitment to developing innovative therapies that address critical unmet medical needs in the neurological space. For more information on Acadia Pharmaceuticals, visit their website or follow their updates on social media.
MWN-AI** Analysis
Acadia Pharmaceuticals (Nasdaq: ACAD) is poised to gain substantial attention following its robust presentation lineup at the upcoming 2025 International Congress of Parkinson’s Disease and Movement Disorders. The focus on its investigational drug ACP-711, aimed at treating essential tremor, could signal important advancements in Acadia’s development pipeline. Additionally, the Phase 2 study for ACP-204 targeting Lewy body dementia psychosis presents promising therapeutic opportunities within a growing market.
Investors should closely monitor the late-breaker presentation regarding ACP-711, highlighting its mechanism of action, preclinical efficacy, and safety data. Given the increasing prevalence of movement disorders, a successful outcome could bolster Acadia's market position and validate its innovative approach, which leverages GABA A subunit modulation. A strong reception could catalyze stock gains, particularly given the novelty of targeting essential tremor, which remains underserved in treatment options.
The encore presentation of findings from NUPLAZID, detailing response duration in Parkinson’s disease psychosis, is another aspect that could impact market sentiment. With NUPLAZID being the only FDA-approved treatment for this condition, solidifying its efficacy data could reassure investors about existing revenue sources while showcasing the company’s commitment to ongoing improvement of treatment outcomes.
However, potential investors should remain cautious. The market for psycholeptics, especially within dementia-related indications, is heavily scrutinized due to safety warnings, including increased mortality risks in elderly patients. Continued vigilance on Acadia's regulatory correspondence and adverse event reporting will be essential.
In summary, Acadia Pharmaceuticals showcases strong potential ahead of the conference; attention should be paid to the reception of clinical data, market conditions for neurological treatments, and the overall competitive landscape. Staying informed and agile could lead to strategic investment opportunities in anticipation of future regulatory and market developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson’s Disease and Movement Disorders ® being held October 5-9, 2025, in Honolulu, Hawaii.
The presentations highlight updates from the company’s robust pipeline including preclinical efficacy, safety and mechanism of action findings on Acadia’s investigational drug ACP-711, under development for essential tremor, as well as a report on the study design of the Phase 2 ACP-204 study in adults with Lewy body dementia psychosis. The company will also present encore findings from a post-hoc analysis of clinical trial data evaluating duration of illness and response to NUPLAZID ® (pimavanserin) in Parkinson’s disease psychosis.
Late-Breaker Oral Platform Presentation:
- Session OPP9/Abstract LBA9/Room 315: Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of SAN711/ACP-711, a Novel GABA A Subunit ? 3 Selective Modulator, Wednesday, October 8 at 12:00-1:00 p.m. HST
Poster Presentations:
- E-Poster 1229: Design of the Phase 2, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of ACP-204, a Novel 5-HT2A Inverse Agonist/Antagonist, in Adults with Lewy Body Dementia Psychosis Tuesday, October 7 at 12:18 p.m. HST
- E-Poster 1225: Duration of Illness and Response to Pimavanserin in Parkinson’s Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data, Tuesday, October 7 at 12:06 p.m. HST
About NUPLAZID ® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.
Indication
NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Important Safety Information
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.
- Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
- Warnings and Precautions: QT Interval Prolongation
- NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
- NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
- Adverse Reactions: The adverse reactions (?2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
- Drug Interactions:
- Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
- Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
Dosage and Administration
Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please read the full Prescribing Information , including Boxed WARNING , also available at NUPLAZIDhcp.com .
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X .
View source version on businesswire.com: https://www.businesswire.com/news/home/20251002463817/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
FAQ**
How will the late-breaker presentation on ACP-7at the International Congress of Parkinson’s Disease impact ACADIA Pharmaceuticals Inc. (ACAD) share price and investor sentiment moving forward?
What are the anticipated timelines for the Phase 2 ACP-204 study results in Lewy body dementia psychosis, and how might this affect ACAD's future development plans?
Given the safety warnings associated with NUPLAZID, how does ACADIA Pharmaceuticals Inc. (ACAD) plan to address regulatory concerns and reassure investors?
How do the findings presented at the congress bolster ACADIA Pharmaceuticals Inc.'s (ACAD) position in the market for treatments addressing Parkinson’s disease psychosis and related disorders?
**MWN-AI FAQ is based on asking OpenAI questions about ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD).
NASDAQ: ACAD
ACAD Trading
-1.34% G/L:
$21.025 Last:
573,736 Volume:
$21.41 Open:
